 |
Depósito mínimo $50 Promoção exclusiva |
Nossa pontuação |
0% comissão |
Are you looking to buy United Therapeutics stocks? Chech our Reportlab with an in-depth review, check prices, statistics and see if buying this stock is interesting right now. This article will help you buy NASDAQ:UTHR! and analyze the company to see if this stock might be an interesting option to invest in. We will enlighten you about United Therapeutics stocks and how to buy and use them. Click on the button to start reading the review right now or scroll down for real time statistics about this company.
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and internationally. The company’s commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma. It also engages in developing OreniPro, RemoPro, Treprostinil Technosphere, Trevyent, Ralinepag, and Aurora-GT to treat PAH; LNG01 to treat IPF; Unexisome to treat BPD; and the research and development of various organ transplantation-related technologies, including regenerative medicine, xenotransplantation, biomechanical lungs, and ex-vivo lung perfusion, as well as the development of medicine for other diseases. The company has licensing and collaboration agreements with Medtronic, Inc. to develop and commercialize the implantable system for Remodulin; Caremark, L.L.C. to provide refills of implanted pumps at its infusion centers; DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of Remodulin; MannKind Corporation to develop and license treprostinil inhalation powder, and Dreamboat and Cricket devices; Arena Pharmaceuticals, Inc. to develop ralinepag for the treatment of PAH; and Samumed LLC to develop LNG01. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.
Volume médio
341,071 shs
MERCADO CAP
$7.56 billion
Bolsa de Valores
NASDAQ
Comprem essas ações!
|
NOME
|
TICKER
|
INDÚSTRIA
|
SECTOR
|
VOLUME
|
COMPRAR AGORA ESSAS AÇÕES
|
|---|---|---|---|---|---|
|
NASDAQ:UTHR
|
Preparações farmacêuticas
|
Médico
|
3,589 shs
|
Below is a quick guide on how to buy NASDAQ:UTHR stocks safe, fast and around the world in less than five minutes.
Passo 1: Abrir uma conta no eToro – eToro is the best broker to buy United Therapeutics shares in the world as you won’t pay any commissions. To do this, visit the eToro website and open an account, it is 100% safe and they offer a huge amount of stocks.
Passo 2: Carregue sua identificação - Conforme os regulamentos da KYC, eToro lhe pedirá que carregue uma cópia de seu passaporte ou de sua carteira de motorista.
Etapa 3: Fundos de depósito - Deposite algum dinheiro em sua recém-criada conta eToro. O senhor pode escolher entre transferência bancária, carteira eletrônica, cartão de débito/crédito ou Paypal.
Passo 4: Buy United Therapeutics – Search for “”NASDAQ:UTHR”” and click on the “”Trade”” button. Enter the total amount of your investment (minimum $50) and confirm the order by clicking the “”Open Trade”” button. And that’s it: you have just bought United Therapeutics stocks with 0% commission!.
1 | | Depósito mínimo $50 Promoção exclusiva | Nossa pontuação 10 ★★★★★ | 0% comissão |
8 Wall Street analysts have issued “buy,” “hold,” and “sell” ratings for United Therapeutics in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should “buy” United Therapeutics stock.
Wall Street analysts have given United Therapeutics a “Buy” rating, but there may be better short-term opportunities in the market. Some of Reportlab’s past winning trading ideas have resulted in 5-15% weekly gains. Reportlab just released five new trading ideas, but United Therapeutics wasn’t one of them. Reportlab thinks five stocks may be even better buys in the how to buy stocks guide.
1 | | Depósito mínimo $50 Promoção exclusiva | Nossa pontuação 10 ★★★★★ | 0% comissão |
2 |  | Depósito mínimo $50 Promoção exclusiva | Nossa pontuação 10 ★★★★★ | 0% comissão |
3 |  | Depósito mínimo $50 Promoção exclusiva | Nossa pontuação 10 ★★★★★ | 0% comissão |
It can be difficult to navigate through all the outdated and incorrect information related to purchasing NASDAQ:UTHR stocks. We believe that stocks should be accessible for all, which is why we’ve created this handy guide on where to buy United Therapeutics stocks with a step by step approach.
You’ll need to register with a broker, in these times you can’t go without once and it’s crucial to use a regulated broker that’s allowed to operate there, otherwise, you risk losing funds. eToro is one such broker, and one of the best brokers to buy United Therapeutics stocks with 0% comission, to sign up just click on open account in the following table or compare other options.
Como o eToro é uma plataforma regulamentada, o senhor precisará completar o processo KYC, isso é uma prática padrão e leva apenas alguns minutos. O senhor precisará fornecer um documento de identificação com foto (passaporte, carteira de motorista) e comprovante de endereço (conta de serviços públicos, extrato bancário).
Uma vez que o senhor tenha se inscrito e verificado sua conta, precisará depositar fundos. eToro aceita cartões de crédito/débito, transferências bancárias, e também carteiras eletrônicas. Portanto, qualquer que seja sua preferência, haverá algo para o senhor.
Now that you’ve funded your eToro account, just type “NASDAQ:UTHR stocks” na barra de busca na parte superior da tela e pressione "trade".
All that’s left is to buy some NASDAQ:UTHR stock. Simply enter the amount you want to purchase and hit the “buy” button. The amount you bought will be automatically credited to your account where you can monitor its performance.
All in all, NASDAQ:UTHR is an incredibly interesting company that has the potential to solve some major issues in the business space. After reading this guide you should know how to buy this investment using the best broker or platform. We recommend eToro to anyone looking for a regulated, easy-to-use, fully-featured broker to buy United Therapeutics stocks. As with any broker or online platform, it’s crucial you set up 2FA when using their tools as it ensures your funds are completely safe.
United Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, February 24th 2021.
View our earnings forecast for United Therapeutics.
United Therapeutics Co. (NASDAQ:UTHR) released its quarterly earnings results on Wednesday, October, 28th. The biotechnology company reported $3.84 earnings per share for the quarter, topping analysts’ consensus estimates of $2.41 by $1.43. The biotechnology company had revenue of $380.10 million for the quarter, compared to analysts’ expectations of $357.95 million. United Therapeutics had a trailing twelve-month return on equity of 15.48% and a net margin of 33.25%. United Therapeutics’s revenue was down 5.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $3.83 earnings per share.
View United Therapeutics’ earnings history.
United Therapeutics’ stock was trading at $93.99 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, UTHR shares have increased by 80.4% and is now trading at $169.60.
8 brokers have issued 1-year target prices for United Therapeutics’ shares. Their forecasts range from $123.00 to $255.00. On average, they expect United Therapeutics’ stock price to reach $188.14 in the next year. This suggests a possible upside of 10.9% from the stock’s current price.
View analysts’ price targets for United Therapeutics or view top-rated stocks among Wall Street analysts.
Launched in 2006, eToro is, in our opinion, without a doubt the best broker for buying NASDAQ:UTHR stocks in the world. The onboarding process is simple, it’s designed to make sure even those new to the stock market are ready to start investing the shortest amount of time possible. As a regulated platform you gain several benefits, most importantly, you know they’re not going to run off with your hard-earned money./
Mais de 95% de fundos de clientes são mantidos offline, em câmara fria, o que é crucial para qualquer corretor que administre seus ativos. Independentemente de quão segura deve ser uma plataforma, recomendamos o uso do 2FA para acrescentar uma camada adicional de segurança à sua conta.
eToro oferece aos usuários uma gama de recursos para começar a investir o mais rapidamente possível. Eles têm uma característica relativamente única chamada negociação de cópias, que lhe permite ganhar uma renda passiva ao espelhar comerciantes experientes, o que lhe permite começar a ter lucro rapidamente, e lhe dá uma melhor compreensão das estratégias usadas pelos profissionais. Além disso, o eToro permite aos usuários investir em carteiras administradas, sendo uma carteira administrada uma variedade de ativos semelhantes agrupados, permitindo ao senhor diversificar sua conta, reduzindo qualquer risco potencial. Para aqueles com experiência anterior em negociação, o senhor pode investir em mercados fora das ações, já que eToro permite aos usuários negociar ETFs, commodities, criptografia e índices. Se o senhor já investir fora do espaço da bolsa de valores, isso pode ser muito útil, pois permite ao senhor administrar todos os seus investimentos em um só lugar.
United Therapeutics’ management team includes the following people:
Dr. Martine A. Rothblatt, Founder, Chairman & CEO (Age 66, Pay $2.98M)
Mr. Michael I. Benkowitz, Pres & COO (Age 49, Pay $1.8M)
Mr. James C. Edgemond, CFO & Treasurer (Age 53, Pay $1.3M)
Mr. Paul A. Mahon, Exec. VP, Gen. Counsel & Corp. Sec. (Age 57, Pay $1.53M)
Mr. Dewey Steadman C.F.A., CFA, Head of Investor Relations
Ms. Holly Hobson, Associate VP of HR
Kevin T. Gray, Sr. VP of Strategic Operations & Logistics
Mr. Patrick Poisson, Exec. VP of Technical Operations (Age 53)
Leigh Peterson, VP of Product Devel.
Mr. Shola Oyewole, VP of Digital Innovation
64 employees have rated United Therapeutics CEO Martine A. Rothblatt on Glassdoor.com. Martine A. Rothblatt has an approval rating of 88% among United Therapeutics’ employees.
Os CFDs são instrumentos complexos e vêm com um alto risco de perder dinheiro rapidamente devido à alavancagem. 68% de contas de investidores de varejo perdem dinheiro ao negociar CFDs com esse provedor. O senhor deve considerar se compreende como os CFDs funcionam, e se pode arcar com o alto risco de perder seu dinheiro.
Some companies that are related to United Therapeutics include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seagen (SGEN), Alexion Pharmaceuticals (ALXN), Exact Sciences (EXAS), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), Novavax (NVAX), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Neurocrine Biosciences (NBIX) and Ionis Pharmaceuticals (IONS).
View all of UTHR’s competitors.
Based on aggregate information from Reportlab watchlists, some companies that other United Therapeutics investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), (CELG), General Electric (GE), Johnson & Johnson (JNJ), Skyworks Solutions (SWKS), Allergan (AGN) and Pfizer (PFE).
United Therapeutics trades on the NASDAQ under the ticker symbol “UTHR.”
United Therapeutics’ stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (9.62%), First Trust Advisors LP (1.91%), Robeco Institutional Asset Management B.V. (1.09%), Russell Investments Group Ltd. (0.86%), Emerald Advisers LLC (0.48%) and Wedge Capital Management L L P NC (0.45%). Company insiders that own United Therapeutics stock include Christopher Patusky, Judy D Olian, Martine A Rothblatt, Raymond Dwek, Richard Giltner and Tommy G Thompson.
View institutional ownership trends for United Therapeutics.
1 | | Depósito mínimo $50 Promoção exclusiva | Nossa pontuação 10 ★★★★★ | 0% comissão |
UTHR stock was sold by a variety of institutional investors in the last quarter, including AJO LP, State of Michigan Retirement System, Russell Investments Group Ltd., Wedge Capital Management L L P NC, BlackRock Inc., Robeco Institutional Asset Management B.V., Greylin Investment Mangement Inc., and Hussman Strategic Advisors Inc.. Company insiders that have sold United Therapeutics company stock in the last year include Judy D Olian, Martine A Rothblatt, Raymond Dwek, Richard Giltner, and Tommy G Thompson.
View insider buying and selling activity for United Therapeutics or view top insider-selling stocks.
UTHR stock was bought by a variety of institutional investors in the last quarter, including Clark Capital Management Group Inc., Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, California Public Employees Retirement System, American Assets Investment Management LLC, Comerica Bank, Aperio Group LLC, and State of Alaska Department of Revenue.
View insider buying and selling activity for United Therapeutics or or view top insider-buying stocks.
Shares of UTHR can be purchased through any online brokerage account. Popular online brokerages with access to the stock market include Revisão dos Corretores Interativos, Revisão eToro, Revisão DEGiro, Revisão da AvaTrade, IG Markets Review, Revisão dos Mercados de IC, CMC Markets Review, Admiral Markets Review e muitos mais. Leia uma das revisões para saber tudo sobre o corretor e comece agora a comprar ações.
One share of UTHR stock can currently be purchased for approximately $169.60.
United Therapeutics has a market capitalization of $7.54 billion and generates $1.45 billion in revenue each year. The biotechnology company earns $-104,500,000.00 in net income (profit) each year or ($2.39) on an earnings per share basis.
United Therapeutics employs 920 workers across the globe.
No Reportlab.org queremos garantir que o senhor tenha todas as informações mais relevantes sobre compra de ações. Trazemos-lhe os melhores guias sobre o mercado de ações, com revisões pessoais, informações de base, revisões de plataforma, como fazer e muito mais. Deseja obter outras informações? Então confira os Ações OTC, Ações da NASDAQ, Ações da NYSE, Ações LONES, Ações de FRA, Ações ETR, Ações da APE, Ações TSX ou Ações Amex. Procurando informações mais detalhadas como Ações de 5g, ações biotecnológicas, estoques de ouro e outras informações de nosso reportlab.
How can you buy United Therapeutics stock on the internet?
You can easily buy United Therapeutics stocks with one of the well known regulated brokers on the internet. You can open an account within 5 minutes, make deposits with countless payment providers and trade with professional tools on their platform. At the moment, our visitors rate eToro as the most popular choice.
Outra opção é usar um corretor regulamentado como Mercados de IC ou Corretores Interativos. You can an account with these brokers and start buying or trading NASDAQ:UTHR stocks in a safe and complete environment to trade in.
Where to buy United Therapeutics stock?
You will first want to find a licensed broker that supports NASDAQ:UTHR stock. One of our favourite brokers, eToro for example, allows you to make investments into this asset from just $25 and only charges you the spread. Another option is using a regulated broker like DEGIRO or Interactive Brokers. You can open an account with these brokers and start buying or trading NASDAQ:UTHR stocks in a safe and complete environment.
Is NASDAQ:UTHR stock a good investment?
As with any other asset, there is an element of risk associated with buying NASDAQ:UTHR stocks. Therefore, you will want to study the market and make a decision based on your financial standing and the risk you are willing to take.
Is United Therapeutics stock safe to invest in?
All stocks are volatile, or affected by market circumstances. The case with NASDAQ:UTHR is no different, with its price fluctuating dramatically within short periods. As such, if the market goes against you, then you will end up facing a loss. We advice you to do research first before investing in United Therapeutics stock.
How do you trade United Therapeutics stocks?
You can trade stocks by first opening an account with a regulated platform and making a deposit in US dollars, EUROs or other currency. Next, search for United Therapeutics stock and choose from a buy or sell order – depending on whether you think the stock asset will rise or fall in value. If you speculated on NASDAQ:UTHR stocks correctly, you will have made a profit. The size of your trading profit will ultimately be determined by your stake and at what percentage your position grew.
How to sell United Therapeutics stock?
To sell your NASDAQ:UTHR stocks investment, you can sign in to your broker account and cash out directly from within your portfolio. If you have stored the stocks elsewhere, you will first have to transfer them to a third-party provider or broker to cash out.
What is the best United Therapeutics stock trading platform?
eToro, is a top-rated platform for beginners, albeit, it charges significantly lower fees. For example, there are no fees to deposit with a debit/credit card and you only need to cover the spread when trading NASDAQ:UTHR stock.
Stephen sabe muito sobre produtos financeiros e, em particular, tem uma grande paixão pelas bolsas de valores e por seus participantes. Esperamos que a informação fornecida ajude o senhor. Algo não está muito claro? Queira deixar suas perguntas ou comentários no final da página.
| Nossa pontuação ★★★★★ | |
| Nossa pontuação ★★★★★ | |
| Nossa pontuação ★★★★★ |
Boletim informativo
Notícias recentes
| |
Nossa pontuação |
0% comissão |
Ações em tempo real e dados criptográficos
Notificações, Dicas e Notícias
Melhores Ações e Guias Criptográficos
Corretor Online & Câmbio de Revisões
Reportlab Finanças é puramente um website informativo e em nenhum caso implica aconselhamento sobre investimentos. Todos os investimentos comportam riscos e o senhor pode perder todos os seus investimentos. Não invista dinheiro que o senhor não pode perder.
Reportlab Finanças
38 Holburn Lane
Heckfield Green
IP21 0UB
Reino Unido
Copyright © 2022 Reportlab.Finance | Todos os direitos reservados.
